Kexing Biopharm Co., Ltd. (SHA:688136)

China · Delayed Price · Currency is CNY

16.00

+0.47 (3.03%)

Nov 5, 2026, 3:00 PM CST

Kexing Biopharm Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,300	1,534	1,407	1,259	1,316	1,285
Revenue Growth	-14.26%	9.03%	11.75%	-4.32%	2.39%	5.32%
Gross Profit	717.45	969.71	962.73	888.72	991.21	1,020
Operating Income	-154.96	88.08	98.52	-240.71	-125.34	42.21
Net Income	70.36	155.57	31.48	-190.29	-90.3	96.46
Earnings Per Share	0.35	0.79	0.16	-0.96	-0.45	0.49
EPS Growth	-42.73%	393.75%	-	-	-	-47.31%

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
China	1,168
Export	366.29
Total	1,534

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	669.6	650.43	554.56	568.8	785.38	877.62
Total Debt	1,511	1,397	1,221	1,116	1,039	601.27
Net Cash (Debt)	-841.86	-746.33	-666.22	-547.26	-253.16	276.35
Net Cash Growth	-	-	-	-	-	-64.88%
Net Cash Per Share	-4.25	-3.79	-3.39	-2.76	-1.26	1.40

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	99.74	86.03	106.67	-87.14	-85.89	94.01
Capital Expenditures	-101.17	-83.63	-93.99	-191.2	-399.17	-371.98
Free Cash Flow	-1.43	2.4	12.68	-278.34	-485.06	-277.97
Free Cash Flow Growth	-	-81.05%	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	55.18%	63.21%	68.43%	70.59%	75.33%	79.36%
Operating Margin	-11.92%	5.74%	7.00%	-19.12%	-9.53%	3.28%
Pretax Margin	6.03%	10.80%	4.04%	-20.66%	-10.57%	7.44%
Profit Margin	5.41%	10.14%	2.24%	-15.11%	-6.86%	7.51%
FCF Margin	-0.11%	0.16%	0.90%	-22.11%	-36.86%	-21.63%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 5, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	0.250	0.250	0.080	-	-	0.100
Dividend Per Share Growth	212.50%	212.50%	-	-	-	25.00%
Dividend Yield	1.56%	0.79%	0.37%	-	-	0.35%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 5, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	45.08	40.33	137.32	-	-	58.23
Forward PE	25.81	38.04	41.58	-	-	-
P/FCF Ratio	-	2611.79	340.98	-	-	-
PS Ratio	2.44	4.09	3.07	3.20	3.24	4.37